College of Pharmacy
Liu Laboratory
Led by Xingui Liu · Medicinal Chemistry
What we study
The Liu Lab discovers and studies small molecules that target E3 ligases, promote protein-protein interactions, or induce protein degradation. They use proximity agents to identify and optimize drug candidates for early drug discovery.
What working here is like
- Wet lab
- Project
- 1
- Papers
- 5
Current projects
PROTAC degraders of Leucine Rich Repeat Kinase 2 (LRRK2)
Developed PROTAC degraders for LRRK2, a target for Parkinson's disease.
Summaries are written by AI in plain language from public symposium abstracts and may be imperfect.
Recent papers, explained
- Discovery of XZ338, a highly potent BCL-XL degrader
2025 · European Journal of Medicinal Chemistry
- Exploiting Avidity Effects for the Discovery of Low Affinity Protein-Binding Fragments
2025 · Journal of Medicinal Chemistry
Uses protein avidity to find weak-binding drug fragments.
Show 3 more papersShow fewer
- Small-molecule degron mimetics for targeted protein degradation
2025 · Essays in Biochemistry
Develops small molecules to trigger protein degradation.
- Stereochemical inversion at a 1,4-cyclohexyl PROTAC linker fine-tunes conformation and binding affinity
2024 · Bioorganic & Medicinal Chemistry Letters
Shows how linker stereochemistry affects PROTAC binding.
- Design and optimization of piperlongumine analogs as potent senolytics
2023 · Bioorganic & Medicinal Chemistry Letters
Plain-language summaries are AI-written and reviewed by us; check the paper for details.
How to reach out
Xingui Liu hasn't set up this page yet. You can also look them up in the UF directory (search “Xingui Liu”).